How cancer treatments and medicines, including cannabis, affect people with multiple myeloma.
A Multicenter Prospective Observational Cohort Study Evaluating the Impact of Cancer-Directed Treatment and Medication Use, Including Cannabis Use, in Multiple Myeloma Patients
This will see if using cannabis changes quality of life, symptoms, or treatment side effects in adults newly diagnosed with multiple myeloma who are receiving first‑line therapy.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 700 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | City of Hope Medical Center Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 11 sites (Goodyear, Arizona and 10 other locations) |
| Trial ID | NCT07225738 on ClinicalTrials.gov |
What this trial studies
This is a multicenter prospective observational cohort that follows newly diagnosed multiple myeloma patients and compares those who use cannabis with those who do not. Participants complete regular patient-reported outcome surveys (FACT-MM and ESAS), undergo blood sample collection, and have clinical adverse events tracked by CTCAE v5.0; a separate survey is collected from participating healthcare providers. The design captures longitudinal symptom and quality-of-life trajectories during the first-line treatment period (up to four cycles) and excludes patients who have had second-line therapy or autologous stem cell transplant. Comparative analyses will estimate potential symptomatic benefits and harms associated with cannabis use while accounting for concurrent cancer-directed treatments.
Who should consider this trial
Good fit: Ideal candidates are adults (≥18) with newly diagnosed, histologically confirmed multiple myeloma who can read English, have ECOG ≤3, have received no more than four cycles of first-line therapy, have not had autologous stem cell transplant, and are willing to complete surveys and blood draws.
Not a fit: Patients who have received five or more cycles, started second-line therapy, undergone autologous stem cell transplant, have another active malignancy, or cannot comply with study assessments are not eligible and are unlikely to benefit from the study's findings.
Why it matters
Potential benefit: If successful, the findings could help patients and clinicians decide whether cannabis might improve symptom control or quality of life during initial multiple myeloma treatment.
How similar studies have performed: Previous small and heterogeneous studies in cancer populations suggest cannabis may relieve pain, nausea, and appetite loss, but rigorous evidence specific to multiple myeloma is limited.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * \* Documented informed consent of the participant * Age: ≥ 18 years * ECOG ≤ 3 * Ability to read and understand English * Patient must be newly diagnosed with a histologically confirmed multiple myeloma * Patients may have started first line therapies and received up to four cycles * HCP SURVEY: Documented informed consent of the participant * HCP SURVEY: Age: ≥ 18 years * HCP SURVEY: Licensed physician, physician assistant, nurse practitioner, or registered nurse * HCP SURVEY: Currently practicing in oncology or providing direct care to oncology patients * HCP SURVEY: Able to read and understand English * HCP SURVEY: Affiliation with City of Hope Exclusion Criteria: * \* Patients may not have completed five cycles of first line therapy or undergone any second line therapy * Other active malignancy * Patients may not have undergone autologous hematopoietic stem cell transplantation * Unable to comply with the study assessments * HCP SURVEY: Reports directly to study PI (Dr. Richard Lee) * HCP SURVEY: Member of the study team or involved in survey design or analysis * HCP SURVEY: Individuals with a real or perceived conflict of interest that could bias survey responses
Where this trial is running
Goodyear, Arizona and 10 other locations
- CTCA at Western Regional Medical Center — Goodyear, Arizona, United States (Not_yet_recruiting)
- City of Hope Medical Center — Duarte, California, United States (Recruiting)
- City of Hope Seacliff — Huntington Beach, California, United States (Not_yet_recruiting)
- City of Hope at Irvine Lennar — Irvine, California, United States (Recruiting)
- City of Hope at Long Beach Elm — Long Beach, California, United States (Not_yet_recruiting)
- City of Hope at Newport Beach Fashion Island — Newport Beach, California, United States (Not_yet_recruiting)
- City of Hope South Pasadena — South Pasadena, California, United States (Not_yet_recruiting)
- City of Hope Upland — Upland, California, United States (Not_yet_recruiting)
- City of Hope West Covina — West Covina, California, United States (Not_yet_recruiting)
- City of Hope Atlanta Cancer Center — Newnan, Georgia, United States (Not_yet_recruiting)
- City of Hope at Chicago — Zion, Illinois, United States (Not_yet_recruiting)
Study contacts
- Principal investigator: Richard T Lee — City of Hope Medical Center
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.